The filing covers the sale of the company's common stock, preferred stock, depositary warrants, subscription rights, contingent value rights, debt securities, purchase contracts and units.
Unless otherwise stated in a prospectus supplement, the company expects to use the net proceeds from the sale of securities for general corporate purposes, including research and development costs, payment obligations and capital expenditures.